The results from the Pr. Frédéric Laurent’s team (National Reference Center for Staphylococci) have been published at the 46th "Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse" (RICAI) in Paris in december 2024.
The poster shows that the MOLSID biotracer demonstrates 100% sensitivity and specificity for the detection of beta-lactamase activity, both in S. aureus and in other staphylococcal species encountered in clinical practice, whatever the beta-lactamase type.
This is the only reliable phenotypic test available on the market that can solve any ambiguity regarding the presence of active penicillinase in methicillin-sensitive staphylococci, in addition to the antibiogram.
Recent posts
It was a pleasure for MOLSID, represented by its Executive Director Younes Lazrak, to present our product pipeline at this year’s ESCMID GLOBAL. Many thanks
A new fundraising round has been opened and will close in Q1 2024, with existing and new investors. This round will allow us to speed
We have updated our corporate clip. Have a look to learn more about who we are and what we do!
